Leiden, 1 April 2023 – BIMINI Biotech, an innovative therapeutics startup, was recently awarded a Eureka Eurostars project with the aim of developing novel therapeutics for lymphomas. This project named HEMATO-WASP, brings together a unique consortium consisting of BIMINI Biotech (Leiden, the Netherlands), InnoSer Nederland… Lees verder »Eurostars project HEMATO-WASP awarded
Compound BM-011 (also known as EG-011) has been selected as molecule of the month November 2022 by Drug Hunter. Drug Hunter™ is an essential resource for the community of R&D innovators turning molecules into medicines. Drug Hunter distills the science behind emerging drugs and technologies… Lees verder »BM-011 molecule of the month
Leiden, 19 January 2023 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has signed an exclusive license agreement with the Institute of Oncology Research (IOR) to acquire and further develop a novel first-in-class Wiskott Aldrich Syndrome protein (WASp) activator. The company… Lees verder »BIMINI Biotech and Institute of Oncology Research enter an exclusive license agreement
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the MCL-TX project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of… Lees verder »BIMINI Biotech awarded the MIT Feasibility grant
BIMINI Biotech was recently awarded a Eureka Eurostars project with the aim of targeting the growth hormone receptor for novel and personalized cancer therapeutics. This project named ONCO-TARGET, brings together a unique consortium consisting of BIMINI Biotech (drug development), Specs Compound Handling (chemistry), Uppsala University… Lees verder »Our collaboration project ONCO-TARGET has been awarded by EUREKA Eurostars!
Leiden, 15 October 2021 – BIMINI Biotech, an innovative therapeutics start-up that develops new cancer drugs, raised an investment of €250,000. The seed funding is provided by Libertatis Ergo Holding B.V. (LEH), a wholly owned subsidiary of Leiden University which supports and invests in spinout… Lees verder »BIMINI Biotech closes seed investment with Libertatis Ergo Holding
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the ONCO-ID project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of… Lees verder »BIMINI received a MIT feasibility grant
Leiden, 26 November 2020 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has secured an investment of €200,000 from proof-of-concept fund UNIIQ to further develop its technology. The company aims to use the growth hormone receptor to uniquely inhibit cancer cell… Lees verder »UNIIQ invests €200,000 in novel cancer therapeutics startup BIMINI Biotech
BIMINI Biotech is one of the 10 winners of the Academic Startup Competition 2020 and is now entitled to use the title ‘Best Academic Startup of 2020’ for the coming year. The other winning startups are DeNoize, Digi Bio, IamFluidics, Kaminari Medical, Lusoco, NC Biomatrix,… Lees verder »Utrecht University spinoff hits Top 10 list of most ground-breaking academic startups
BIMINI Biotech has been nominated from no fewer than an astounding 57 contenders, by the Association of Universities in the Netherlands (Vereniging van Universiteiten (VSNU), the Netherlands Academy of Technology and Innovation (AcTI) and Techleap as one of the 20 academic startups to compete in… Lees verder »BIMINI Biotech in the race to become the ‘Best Academic Startup of the Netherlands’